Week 7
1. Appraise the systematic review research study using the Johns Hopkins
Research Appraisal Tool. Transfer your findings to the Johns Hopkins
Individual Evidence Summary Tool.
2. Determine whether the research design – systematic review, systematic review
with meta-analysis, or meta-synthesis – answers the research question. Explain
your rationale.
3. Based on information in the published study, explain if the search was
comprehensible and reproducible.
4. Based on the Johns Hopkins Individual Evidence Summary To l, determine if
there is an evidence-based intervention you might consider for translation to
practice in a practice change project. Explain your rationale.
5. Based on the Johns Hopkins Individual Evidence Summary To l Column
Observable Measures, consider if you would use this systematic review research
study as sup ort for your selected practice problem. Explain your rationale.
The sixth most prevalent and third-leading cause of cancer-related mortality is liver cancer
(Singh et al., 2020). According to Singh et al. (2020), dysplastic micronodules in
hepatocellular carcinoma (HCC) evolve early and develop into cancer. Therefore, screening
should enable us to find lesions early. The study by Zheng et al. (2017) aimed to assess the
prognostic value of lncRNA as a marker for patients with hepatocellular carcinoma (HCC).
The necessary information in this study was meticulously extracted after a thorough search of
the PubMed and Embase databases on the predictive efficacy of various lncRNAs in HCC; the
essential information was rigorously gathered and analyzed using meta-analysis. According to
40 associative studies, HCC patients with a worse prognosis had high expression of 27 types
of lncRNA, while those with a worse prognosis had low expression of 18. The meta-analysis
showed that the levels of lncRNA expression are an excellent way to predict how long HCC
patients will live. The research work is intelligible and replicable since it used a systematic
search and a complete analytic approach to analyze lncRNAs in HCC patients. The study's
methods were extensive and followed the rules for doing and writing systematic reviews.
According to recent studies, lncRNAs, as hepatoma-specific tumor markers, have over 200
biological roles that help diagnose and treat liver cancer, as confirmed by Zheng et al. (2017).
References
Singh, G., Yoshida, E. M., Rathi, S., Marquez, V., Kim, P., Erb, S. R., & Salh, B. S.
(2020). Biomarkers for hepatocellular cancer. World Journal of Hepatology, 12(9), 558-
573. https://doi.org/10.4254/wjh.v12.i9.558
Zheng, C., Liu, X., Chen, L., Xu, Z., & Shao, J. (2017). lncRNAs as prognostic molecular
biomarkers in hepatocellular carcinoma: A systematic review and meta-analysis.
Oncotarget, 8(35), 59638-59647. https://doi.org/10.18632/oncotarget.19559
https://chamberlain.primo.exlibrisgroup.com/permalink/01CUCON_INST/f6kb8f/
cdi_pubmedce ntral_primary_oai_pubmedcentral_nih_gov_5601763
1. Appraise the systematic review research study using the Johns Hopkins
Research Appraisal Tool. Transfer your findings to the Johns Hopkins
Individual Evidence Summary Tool.
2. Determine whether the research design – systematic review, systematic review
with meta-analysis, or meta-synthesis – answers the research question. Explain
your rationale.
3. Based on information in the published study, explain if the search was
comprehensible and reproducible.
4. Based on the Johns Hopkins Individual Evidence Summary To l, determine if
there is an evidence-based intervention you might consider for translation to
practice in a practice change project. Explain your rationale.
5. Based on the Johns Hopkins Individual Evidence Summary To l Column
Observable Measures, consider if you would use this systematic review research
study as sup ort for your selected practice problem. Explain your rationale.
The sixth most prevalent and third-leading cause of cancer-related mortality is liver cancer
(Singh et al., 2020). According to Singh et al. (2020), dysplastic micronodules in
hepatocellular carcinoma (HCC) evolve early and develop into cancer. Therefore, screening
should enable us to find lesions early. The study by Zheng et al. (2017) aimed to assess the
prognostic value of lncRNA as a marker for patients with hepatocellular carcinoma (HCC).
The necessary information in this study was meticulously extracted after a thorough search of
the PubMed and Embase databases on the predictive efficacy of various lncRNAs in HCC; the
essential information was rigorously gathered and analyzed using meta-analysis. According to
40 associative studies, HCC patients with a worse prognosis had high expression of 27 types
of lncRNA, while those with a worse prognosis had low expression of 18. The meta-analysis
showed that the levels of lncRNA expression are an excellent way to predict how long HCC
patients will live. The research work is intelligible and replicable since it used a systematic
search and a complete analytic approach to analyze lncRNAs in HCC patients. The study's
methods were extensive and followed the rules for doing and writing systematic reviews.
According to recent studies, lncRNAs, as hepatoma-specific tumor markers, have over 200
biological roles that help diagnose and treat liver cancer, as confirmed by Zheng et al. (2017).
References
Singh, G., Yoshida, E. M., Rathi, S., Marquez, V., Kim, P., Erb, S. R., & Salh, B. S.
(2020). Biomarkers for hepatocellular cancer. World Journal of Hepatology, 12(9), 558-
573. https://doi.org/10.4254/wjh.v12.i9.558
Zheng, C., Liu, X., Chen, L., Xu, Z., & Shao, J. (2017). lncRNAs as prognostic molecular
biomarkers in hepatocellular carcinoma: A systematic review and meta-analysis.
Oncotarget, 8(35), 59638-59647. https://doi.org/10.18632/oncotarget.19559
https://chamberlain.primo.exlibrisgroup.com/permalink/01CUCON_INST/f6kb8f/
cdi_pubmedce ntral_primary_oai_pubmedcentral_nih_gov_5601763
